Chimeric antigen receptor (CAR) T cell therapy involves modified T cells to create distinct antibodies that can detect and cling to antigens on cancerous cells. Tumor-infiltrating lymphocyte (TIL) therapy is a potentially effective cancer treatment strategy. The application of nanoparticles in drug ...
with the emergence of new immunotherapy and targeted therapies for patients at various stages of the disease (Fig.1). In this review, we systematically summarize the pivotal clinical trials in GC treatment and provide an update on the management of localized and metastatic gastric cancer. We ...
AqB011 holds promise as a possible adjunct treatment for controlling cancer metastasis, by blocking the AQP1 ionic conductance that facilitates cancer cell migration in AQP1-positive cancers [25,66]. The medicinal plant component, bacopaside I, similarly blocked the AQP1 ion channel in loop D, ...
Lung cancer continues to be the leading cause of cancer-related death worldwide. In the last decade, significant advancements in the diagnosis and treatment of lung cancer, particularly NSCLC, have been achieved with the help of molecular translational research. Among the hopeful breakthroughs in the...
Recent breakthroughs in cancer therapy have shown a progressive trend away from monotherapy and toward various therapeutic techniques such as synergistic bimodal and trimodal cancer therapies within a single system [3]. Outstanding advantages of nanomaterials have contributed to rapid nanotechnological develop...
Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a poor prognosis. Current treatment options are limited to surgery, adjuvant chemotherapy and radiotherapy; however, a proportion of patients have missed the surgical window at the time of diagnosis. TNBC...
Although the multi-organs-on-a-chip concept remains in its infancy, major breakthroughs have been made, including the design of two-organs [104, 105], three-organs [106, 107], four-organs [108, 109], and ten organs on the chip [110]....
Recent breakthroughs in exploring the tumour immune microenvironment have opened new avenues for the development of immunotherapies [110]. Immunotherapy, which aims to kill cancer cells by modulating the host immune system, has been applied in the clinical treatment along with surgery, chemotherapy and...
Metastatic colorectal cancer (mCRC) continues to be associated with a poor prognosis, and there remains a significant unmet need for novel agents and treatment regimens. Major breakthroughs have been made with immune checkpoint blockade therapy in several disease types, including DNA mismatch repair de...
Collectively, immunotherapy has advanced the treatment for EC and G/GEJC with significant breakthroughs in CRC, although several challenges remain to be addressed, including the diversity and complex molecular types in GC, the optimal treatment regimen for MSI-H/dMMR CRC, the potential for immunothe...